At the time of writing, Bluebird bio Inc [BLUE] stock is trading at $1.26, up 8.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The BLUE shares have gain 4.13% over the last week, with a monthly amount drifted -16.00%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance. In a post published today on Yahoo Finance, – Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -.
From an analyst’s perspective:
Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on December 11, 2023, when HSBC Securities downgraded its rating to a Reduce. Previously, Morgan Stanley upgraded its rating to Equal-Weight on December 08, 2023, and elevated its price target to $7. On October 17, 2023, Cantor Fitzgerald initiated with a Neutral rating. HSBC Securities started tracking the stock assigning a Buy rating and suggested a price target of $4.21 on September 06, 2023. BofA Securities upgraded its rating to a Buy and raised its price target to $10 on July 19, 2023. Barclays upgraded its rating to Overweight for this stock on June 01, 2023, and upped its price target to $8. In a note dated April 28, 2023, JP Morgan initiated an Overweight rating and provided a target price of $7 on this stock.
For the past year, the stock price of Bluebird bio Inc fluctuated between $0.88 and $5.53. Currently, Wall Street analysts expect the stock to reach $14.13 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $1.26 at the most recent close of the market. An investor can expect a potential return of 1021.43% based on the average BLUE price forecast.
Analyzing the BLUE fundamentals
According to Bluebird bio Inc [NASDAQ:BLUE], the company’s sales were 21.73M for trailing twelve months, which represents an 17353.52% jump. Gross Profit Margin for this corporation currently stands at -0.1% with Operating Profit Margin at -6.27%, Pretax Profit Margin comes in at -4.2%, and Net Profit Margin reading is -3.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.29 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1867 points at the first support level, and at 1.1133 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2967, and for the 2nd resistance point, it is at 1.3333.
Bluebird bio Inc [BLUE] reported earnings per share of -$0.66 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.67/share, meaning a difference of $0.01 and a surprise factor of 1.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.67 per share as compared to estimates of -$0.72 per share, a difference of $0.05 representing a surprise of 6.90%.
Ratios To Look Out For
It is important to note that Bluebird bio Inc [NASDAQ:BLUE] has a current ratio of 1.55. On the other hand, the Quick Ratio is 1.42, and the Cash Ratio is 1.04. Considering the valuation of this stock, the price to sales ratio is 11.18, the price to book ratio is 0.61.
Transactions by insiders
Recent insider trading involved Obenshain Andrew, President and CEO, that happened on Mar 04 ’24 when 6095.0 shares were sold., Klima Thomas J completed a deal on Mar 04 ’24 to sell 4573.0 shares. Meanwhile, Chief Medical Officer Colvin Richard A sold 6770.0 shares on Mar 01 ’24.
